Trials / Completed
CompletedNCT06273371
Tolerance and Growth Outcomes in Children Diagnosed With Cow's Milk Protein Allergy and Prescribed an Extensively Hydrolyzed Casein Formula (Damira 2000©) in Spain
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 61 (actual)
- Sponsor
- Lactalis · Industry
- Sex
- All
- Age
- 0 Months – 12 Months
- Healthy volunteers
- —
Summary
Damira 2000© is a 100% extensive casein hydrolysate (eHCF). It is formulated to help reverse growth retardation as a result of cow's milk proteins allergy (CMPA), to be well tolerated and to help improve symptoms.Damira 2000 is indicated for allergy/intolerance to cow's milk proteins, atopic dermatitis secondary to CMPA, intestinal malabsorption processes and prevention of allergy/intolerance to cow's milk proteins.The study aimed at evaluating the tolerance of Damira 2000 in a cohort of children with CMPA.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Damira 2000 Infant formula | 100% extensive casein hydrolysate Infant formula |
Timeline
- Start date
- 2023-12-12
- Primary completion
- 2023-12-21
- Completion
- 2023-12-21
- First posted
- 2024-02-22
- Last updated
- 2024-02-22
Locations
8 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT06273371. Inclusion in this directory is not an endorsement.